GlassScriptPhysician profile
Thippeswamy H Murthy
NPI 1447255617
$4,438.15
in general payments reported to CMS, 2019-2025
31 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $226 · 2021: $863 · 2022: $538 · 2023: $962 · 2024: $210 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $717.12 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $645.43 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $410.28 | 2019-2023 | Opsumit |
| Pfizer INC. | $378.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $284.34 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $263.46 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $246.64 | 2019-2024 | Lifevest |
| Medtronic, INC. | $211.75 | 2023 | Micra |
| Medtronic Vascular, INC. | $146.67 | 2019 | |
| Merck Sharp & Dohme LLC | $127.52 | 2022-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $125.15 | 2019-2024 | Andexxa |
| Abbott Laboratories | $118.68 | 2020-2025 | Cardiomems, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.27 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $82.38 | 2019-2025 | General - Therapies, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $71.53 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $70.80 | 2021-2022 | |
| Edwards Lifesciences Corporation | $64.67 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kiniksa Pharmaceuticals, LTD. | $62.14 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $57.89 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $40.75 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $38.71 | 2022-2023 | Nexletol |
| Ionis Pharmaceuticals, INC. | $25.85 | 2025 | Tryngolza |
| Lantheus Medical Imaging, INC. | $23.23 | 2022 | |
| Amarin Pharma, INC. | $23.15 | 2019 | |
| Atricure, INC. | $20.50 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Alnylam Pharmaceuticals INC. | $17.90 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $17.81 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $17.74 | 2023 | Livalo |
| Hydrofera LLC | $16.30 | 2025 | Hydrofera Blue |
| Heartflow, INC. | $14.90 | 2022 | |
| Gilead Sciences, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thippeswamy Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.